{"id":"protirelin","rwe":[],"tags":[{"label":"protirelin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Thyrotropin-releasing hormone receptor","category":"target"},{"label":"TRHR","category":"gene"},{"label":"V04CJ02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Diagnostic Test for Thyroid Dysfunction","category":"indication"},{"label":"Pituitary Function Studies","category":"indication"},{"label":"Approved 1970s","category":"decade"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PROTIRELIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:12:32.759729+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:39.577997+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROTIRELIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:40.385982+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thyrotropin-releasing hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:40.954078+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1472/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:40.854648+00:00"}},"allNames":"lopremone","offLabel":[],"synonyms":["protirelin tartrate","protirelin","lopremone","rifathyroin","rifotironin","TRH"],"timeline":[{"date":"1976-11-05","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Lopremone (Protirelin) is a small molecule drug that targets the thyrotropin-releasing hormone receptor. Originally developed by, it is currently owned by and was FDA approved in 1976 for Diagnostic Test for Thyroid Dysfunction and Pituitary Function Studies. As an off-patent drug, it is not commercially available as a generic. Key safety considerations include its low bioavailability of 2%. Lopremone is used to assess thyroid function and pituitary gland activity.","approvals":[{"date":"1976-11-05","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Lopremone","ecosystem":[{"indication":"Diagnostic Test for Thyroid Dysfunction","otherDrugs":[{"name":"levothyroxine","slug":"levothyroxine","company":"Stevens J"},{"name":"liothyronine","slug":"liothyronine","company":"King Pharms R And D"}],"globalPrevalence":null},{"indication":"Pituitary Function Studies","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Thyrotropin-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"TRHR","source":"DrugCentral","target":"Thyrotropin-releasing hormone receptor","protein":"Thyrotropin-releasing hormone receptor"}],"modality":"Small Molecule","drugClass":"protirelin","explanation":"","oneSentence":"","technicalDetail":"Lopremone acts as a selective agonist at the thyrotropin-releasing hormone (TRH) receptor, triggering a cascade of downstream signaling events that ultimately lead to the release of TSH from the anterior pituitary gland."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-11-05, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2316","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PROTIRELIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROTIRELIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:30:58.471646","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:42.718246+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"thyrotropin alfa","drugSlug":"thyrotropin-alfa","fdaApproval":"1953-05-26","relationship":"same-class"}],"genericName":"protirelin","indications":{"approved":[{"name":"Diagnostic Test for Thyroid Dysfunction","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with thyroid function issues, pituitary or hypothalamic dysfunction"},{"name":"Pituitary Function Studies","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with pituitary or hypothalamic dysfunction"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"thyrotropin-alfa","brandName":"thyrotropin alfa","genericName":"thyrotropin alfa","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04868045","phase":"PHASE1","title":"Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-27","conditions":["Thyroid Cancer"],"enrollment":0,"completionDate":"2023-02-15"},{"nctId":"NCT02399475","phase":"NA","title":"Mechanistic Study of Subclinical Hypothyroidism In the Elderly","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-01-01","conditions":["Subclinical Hypothyroidism"],"enrollment":14,"completionDate":"2019-09-30"},{"nctId":"NCT01970098","phase":"PHASE3","title":"A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-10-09","conditions":["Spinocerebellar Degeneration"],"enrollment":374,"completionDate":"2015-01"},{"nctId":"NCT00054756","phase":"PHASE2","title":"Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-02-07","conditions":["Healthy","Pituitary Disease","Thyroid Disease"],"enrollment":96,"completionDate":"2014-09-26"},{"nctId":"NCT00790296","phase":"PHASE2","title":"Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue","status":"TERMINATED","sponsor":"UConn Health","startDate":"2006-12","conditions":["Cancer-related Fatigue"],"enrollment":11,"completionDate":"2010-03"},{"nctId":"NCT00812149","phase":"","title":"Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-12-17","conditions":["Thyroid Disease","Healthy"],"enrollment":86,"completionDate":"2014-05-16"},{"nctId":"NCT01970137","phase":"PHASE3","title":"A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Spinocerebellar Degeneration"],"enrollment":0,"completionDate":""},{"nctId":"NCT01970124","phase":"PHASE3","title":"A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Spinocerebellar Degeneration"],"enrollment":0,"completionDate":""},{"nctId":"NCT01970111","phase":"PHASE3","title":"An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Spinocerebellar Degeneration"],"enrollment":0,"completionDate":""},{"nctId":"NCT00106119","phase":"PHASE2","title":"Thyroid and Glucose and Energy Metabolism","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-03","conditions":["Thyroid Diseases"],"enrollment":18,"completionDate":"2013-11"},{"nctId":"NCT01384435","phase":"PHASE2","title":"A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["SCD"],"enrollment":200,"completionDate":""},{"nctId":"NCT01004016","phase":"PHASE2","title":"A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Spinocerebellar Degeneration"],"enrollment":20,"completionDate":""},{"nctId":"NCT00863538","phase":"PHASE2","title":"Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Spinocerebellar Degeneration"],"enrollment":40,"completionDate":""},{"nctId":"NCT00004778","phase":"PHASE3","title":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1993-08","conditions":["Respiratory Distress Syndrome"],"enrollment":1090,"completionDate":""},{"nctId":"NCT00004840","phase":"NA","title":"Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1998-05","conditions":["Respiratory Distress Syndrome"],"enrollment":996,"completionDate":"1998-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Solution","formulations":[{"form":"SOLUTION","route":"INTRAVENOUS","productName":"Thyrotropin Releasing HormoneTRH"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000170390","MMSL":"5380","NDDF":"002111","UNII":"5Y5F15120W","VUID":"4018469","CHEBI":"CHEBI:35940","VANDF":"4018469","INN_ID":"3335","RXNORM":"10580","UMLSCUI":"C0040162","chemblId":"CHEMBL1472","ChEMBL_ID":"CHEMBL1472","KEGG_DRUG":"D00176","DRUGBANK_ID":"DB09421","PUBCHEM_CID":"638678","SNOMEDCT_US":"10534002","IUPHAR_LIGAND_ID":"2139","SECONDARY_CAS_RN":"53935-32-3"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"2%"},"publicationCount":121,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"V04CJ02","allCodes":["V04CJ02"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"1976","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1976-11-05T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:42.718246+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}